Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adolescents in Africa.
Brief Summary: Chlorproguanil-dapsone has been approved for the treatment of uncomplicated Plasmodium falciparum malaria in a number of countries across sub-Sahara Africa, and by the UK's Medicines and Healthcare products Regulatory Agency.

CDA is a combination of chlorproguanil, dapsone and artesunate, being developed in a public-private partnership with the Medicines for Malaria Venture (MMV), World Health Organisation (WHO-TDR) and academic partners from the London School of Hygiene and Tropical Medicine, University of Liverpool and the Liverpool School of Tropical Medicine as a treatment for acute uncomplicated P. falciparum malaria.

The combination of chlorproguanil-dapsone-artesunate (CDA) is being developed to supersede chlorproguanil-dapsone for the same indication, but the addition of an artemisinin derivative, artesunate, should provide additional population benefits over chlorproguanil-dapsone alone. The artemisinins have been demonstrated to rapidly reduce parasite load and have activity against the sexual stages of the P.falciparum lifecycle. The addition of a second agent to the chlorproguanil-dapsone combination should also protect against the selection of resistant strains of P.falciparum.

Artemether-lumefantrine is the only available fixed-dose Artemisinin-based Combination Therapy actually available and is considered as the gold standard for the treatment of P. falciparum malaria. This study will therefore aim to demonstrate the non-inferiority of the combination of CDA to artemether-lumefantrine in terms of efficacy at 28-days. The key secondary objectives will compare the Parasite Clearance Times (PCT) and the Fever Clearance Times (FCT) between CDA and artemether-lumefantrine.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2
B: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: artemether-lumefantrine | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: artemether-lumefantrine; Assigned to Arm(s): Arm 1
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)

Answer: C